Sulanemadlin is a Synthetic Peptide owned by Aileron Therapeutics, and is involved in 9 clinical trials, of which 2 were completed, 6 are ongoing, and 1 is planned.

Sulanemadlin (ALRN-6924) acts by inhibiting murine double minute 2 (MDM2) and murine double minute X (MDMX). ALRN-6924 selectively binds to and inhibits both proteins equally, thereby restoring p53 function. The drug candidate binds to the therapeutic target and modulates the interaction between p53 and both of its natural protein suppressors, MDM2 and MDMX. Stapled peptides successfully modulate protein–protein interactions (intracellular and extracellular) relative to Bcl-2 family of apoptotic proteins, glucokinase, p53 transcription factor.

The revenue for Sulanemadlin is expected to reach a total of $1.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Sulanemadlin NPV Report.

Sulanemadlin was originated by Aileron Therapeutics and F. Hoffmann-La Roche and is currently owned by Aileron Therapeutics.

Sulanemadlin Overview

Sulanemadlin (ALRN-6924) is under development for the treatment of solid tumors, small cell lung cancer and pediatric tumors including lymphomas, acute myeloid leukemia acute lymphocytic leukemia, chemotherapy induced myelosuppression in patients with TP53-mutated HER2- breast cancer, retinoblastoma, hepatoblastoma, acute radiation induced toxicity, brain tumor, liposarcoma, ER positive/HER2 negative breast cancer, metastatic breast cancer and chemotherapy-induced hair loss. It is administered through the intravenous route. The drug candidate is a synthetic peptide which is developed based on stapled peptide technology that locks the peptides into certain folded shapes (biologically active shape), that are resistant to proteases. It acts by targeting murine double minute 2 (MDM2) and murine double minute X (MDMX).

The drug candidate was also under development for the treatment of adult peripheral T-cell lymphoma, lymphoma's, acute myeloid leukemia,p53-mutant chemotherapy induced myelosuppression in small cell lung cancer patients, myelodysplastic syndrome and non-small cell lung cancer.

Aileron Therapeutics Overview

Aileron Therapeutics is a biopharmaceutical company. The company discovers, develops, and commercializes novel class of therapeutics. It provides products such as ALRN-692 which is a peptide drug used to treat patients with p53-mutated cancer. ALRN-6924 as an anti-cancer agent including a single-agent Phase 1 trial in solid tumor and lymphoma patients; a Phase 2a trial for the treatment of peripheral T-cell lymphoma; a single-agent Phase 1 trial for the treatment of acute myeloid leukemia, or AML, and advanced high-risk myelodysplastic syndrome (MIDS). The company partners with research organizations to provide its products. Aileron Therapeutics is headquartered in Boston, Massachusetts, the US.

The operating loss of the company was US$26.3 million in FY2021, compared to an operating loss of US$20.5 million in FY2020. The net loss of the company was US$26.2 million in FY2021, compared to a net loss of US$21.2 million in FY2020.

Quick View – Sulanemadlin

Report Segments
  • Innovator
Drug Name
  • Sulanemadlin
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
  • Toxicology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.